Market capitalization | $2.28b |
Enterprise Value | $3.22b |
P/E (TTM) P/E ratio | 23.51 |
EV/FCF (TTM) EV/FCF | 20.21 |
EV/Sales (TTM) EV/Sales | 2.53 |
P/S ratio (TTM) P/S ratio | 1.79 |
P/B ratio (TTM) P/B ratio | 2.58 |
Dividend yield | 1.08% |
Last dividend (FY23) | $0.80 |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
8 Analysts have issued a Conmed Corp. forecast:
8 Analysts have issued a Conmed Corp. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,272 1,272 |
13%
13%
|
|
Gross Profit | 660 660 |
15%
15%
|
|
EBITDA | 208 208 |
63%
63%
|
EBIT (Operating Income) EBIT | 152 152 |
112%
112%
|
Net Profit | 99 99 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Head office | United States |
CEO | Curt Hartman |
Employees | 4,000 |
Founded | 1970 |
Website | www.conmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.